Prognostic value of FDG-PET in patients with oropharyngeal carcinoma treated with concurrent chemoradiotherapy

Molecular Imaging and Biology

Volumn 10, Issue 4, 2008, Pages 224-229

  Enomoto, Keisuke ^a   Inohara, Hidenori ^a   Higuchi, Ichiro ^a   Hamada, Kenichiro ^a   Tomiyama, Yoichiro ^a   Kubo, Takeshi ^a   Hatazawa, Jun ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Carcinoma; Chemoradiotherapy; FDG; HNSCC; Neck; Oropharynx; PET; Prognosis

Indexed keywords

CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MALE; MULTIPLE CYCLE TREATMENT; OROPHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORODEOXYGLUCOSE F18; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TAXOIDS;

EID: 45849084636     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-008-0145-4     Document Type: Article

References (24)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK (1993) Head and neck cancer. N Engl J Med 328:184-194
2. Kleinman DV, Crossett LA, Ries LAG, Goldberg HI, Lockwood SA, Swango PA (1991) Cancers of the oral cavity and pharynx: A statistics review monograph 1973-1987. USDHHS, Public Health Service, Atlanta, GA
3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics. CA Cancer J Clin 57:43-66
4. Cmelak AJ, Li S, Goldwasser MA et al (2007) Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: Results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 25:3971-3977
5. Schuller DE, Ozer E, Agrawal A, Grecula JC, Rhoades CA, Young DC (2007) Multimodal intensification regimens for advanced, resectable, previously untreated squamous cell cancer of the oral cavity, oropharynx, or hypopharynx: A 12-year experience. Arch Otolaryngol Head Neck Surg 133:320-326
6. Schuller DE, Grecula JC, Agrawal A et al (2002) Multimodal intensification therapy for previously untreated advanced resectable squamous cell carcinoma of the oral cavity, oropharynx, or hypopharynx. Cancer 94:3169-3178
7. Licitra L, Bernier J, Grandi C, Merlano M, Bruzzi P, Lefebvre JL (2002) Cancer of the oropharynx. Crit Rev Oncol Hematol 41:107-122
8. Klug C, Wutzl A, Kermer C et al (2005) Preoperative radiochemotherapy and radical resection for stages II-IV oral and oropharyngeal cancer: outcome of 222 patients. Int J Oral Maxillofac Surg 34:143-148
9. Parsons JT, Mendenhall WM, Stringer SP et al (2002) Squamous cell carcinoma of the oropharynx: Surgery, radiation therapy, or both. Cancer 94:2967-2980
10. Kokubo M, Nagata Y, Nishimura Y et al (2001) Concurrent chemoradiotherapy for oropharyngeal carcinoma. Am J Clin Oncol 24:71-76
11. de Cassia Braga Ribeiro K, Kowalski LP, Latorre Mdo R (2003) Perioperative complications, comorbidities, and survival in oral or oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 129:219-228
12. Pugliano FA, Piccirillo JF, Zequeira MR et al (1997) Clinical-severity staging system for oropharyngeal cancer: Five-year survival rates. Arch Otolaryngol Head Neck Surg 123:1118-1124
13. Kim SY, Roh JL, Kim MR et al (2007) Use of 18F-FDG PET for primary treatment strategy in patients with squamous cell carcinoma of the oropharynx. J Nucl Med 48:752-757
14. Kim MR, Roh JL, Kim JS et al (2007) Utility of 18F-fluorodeoxyglucose positron emission tomography in the preoperative staging of squamous cell carcinoma of the oropharynx. Eur J Surg Oncol 33:633-638
15. Schwartz DL, Rajendran J, Yueh B et al (2004) FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 130:1361-1367
16. Sanghera B, Wong WL, Lodge MA et al (2005) Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun 26:861-867
17. Dobert N, Kovacs AF, Menzel C et al (2005) The prognostic value of FDG PET in head and neck cancer. Correlation with histopathology. Q J Nucl Med Mol Imaging. 49:253-257
18. Nayak JV, Walvekar RR, Andrade RS et al Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT. Laryngoscope. in press
19. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
20. Roh JL, Pae KH, Choi SH et al (2007) 2-[18F]-Fluoro-2-deoxy-d-glucose positron emission tomography as guidance for primary treatment in patients with advanced-stage resectable squamous cell carcinoma of the larynx and hypopharynx. Eur J Surg Oncol 33:790-795
21. Swisher SG, Erasmus J, Maish M et al (2004) 2-Fluoro-2-deoxy-d-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 101:1776-1785
22. Kalff V, Duong C, Drummond EG, Matthews JP, Hicks RJ (2006) Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery. J Nucl Med. 47:14-22
23. Eschmann SM, Friedel G, Paulsen F et al (2007) 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer. Eur J Nucl Med Mol Imaging 34:463-471
24. Porceddu SV, Jarmolowski E, Hicks RJ et al (2005) Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 27:175-181